Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q1RMZ1
UPID:
SAMTR_HUMAN
Alternative names:
Probable methyltransferase BMT2 homolog
Alternative UPACC:
Q1RMZ1; Q8N3D0; Q96MV7
Background:
The S-adenosylmethionine sensor upstream of mTORC1, also known as Probable methyltransferase BMT2 homolog, is a pivotal S-adenosyl-L-methionine-binding protein. It regulates mTORC1 signaling through interactions with the GATOR1 and KICSTOR complexes, responding to methionine levels. This protein serves as a methionine sufficiency sensor, promoting or inhibiting mTORC1 signaling based on S-adenosyl-L-methionine availability.
Therapeutic significance:
Understanding the role of S-adenosylmethionine sensor upstream of mTORC1 could open doors to potential therapeutic strategies.